The Toxicology team at Tubulis is dedicated to ensuring the safety and efficacy of our innovative antibody-drug conjugates (ADCs) through rigorous preclinical studies. As a critical component of Tubulis’ Research and Development organization, our team collaborates closely with cross-functional groups, including Research, Early Development, and Clinical Development, to generate high-quality data essential for regulatory submissions and clinical trial applications.
Our current focus is on designing and evaluating pharmacokinetic and toxicological studies to advance Tubulis’ lead candidates toward first-in-human trials. The team thrives in a collaborative, innovative, and supportive environment, fostering a culture of scientific curiosity, open communication, and a shared commitment to improving patient outcomes through cutting-edge biotechnology.